

# Imperial College Healthcare NHS Trust (Hammersmith Hospital Lipids Department)

**Project Name:** Imperial tertiary lipid service development

## **Project Summary:**

The CWP is structured such that a multi-disciplinary health professional team will provide tailored care for patients, aligned with the Primary Care Network (PCN) Contract Direct Enhanced Service (DES) and the locally defined Cardiovascular plans for the enhancement of the tertiary lipid service.

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) in response to the needs of the CW Partner.

The CWP will be led by the CW Partner's Lead Nurse, alongside a multi-disciplinary team; including Lipidologist, Cardiologists, and a Clinical Pharmacist, aiming to achieve:

- Identification of patients with ASCVD and those who are at high risk of, and commence their lipid treatment pathway according to NICE and local guidelines
- Identification of sub-optimally treated ASCVD patients and those at high risk of, who are not achieving lipid levels as specified in local guidelines
- Identification ASCVD patients and those at high risk of, who have previously not tolerated or refused alternative lipid modification therapies
- Review of treatment options and decide the next best course of action in collaboration with ASCVD patients or patients at high risk of ASCVD.
- Counsel ASCVD patients or patients at high risk of ASCVD where appropriate.

This CWP has been amended, to include additional funding for one 1.0 full time equivalent (FTE) band 6 clinical nurse specialist (CNS), and one 0.1 FTE CNS to offer subsequent supervisory support to undertake lipid clinic activities in the CW Partner's hyper-acute stroke unit (HASU). The CW Partner feels the addition to the HASU team will demonstrate a closer working model to that described in the AHSN Pathway

## **Planned Milestones:**

- Collection of baseline data, in line with the above Project Outcome Measures & Data Collection table
- Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity (CW Partner shall ensure that the clinical staff covered by the Novartis Financial Contribution are in place, trained and ready to begin clinical activity).
- Confirmation of CWP roles in place ready to begin the clinical activity
- Collection & submission of 6 months clinical activity data.
- Project Review meeting to discuss project progress.
- Collection & submission of 12 months clinical activity data.
- Project Review meeting to discuss project progress.
- Collection & submission of 18 months clinical activity data.
- Project Review meeting to discuss project progress.

- Development of business case.
- Collection & submission of 24 months clinical activity data.
- Analysis of CWP data, submission of Final Project Report, Submission of Outcomes Summary.
- Project Review/close out meeting.

### **Expected Benefits:**

#### *Patient benefits*

- Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
- Enhanced experience around ASCVD with ongoing management of the condition.
- Improved access to appropriate lipid therapies for suitable patients to preserve health and prevent long-term events

#### *Organisation Benefits*

- Increased proportion of patients who have ASCVD or at high risk of, reviewed by the lipid service
- Increased proportion of patients who have ASCVD or at high risk of, receiving expert and timely reviews
- Increased proportion of patients receiving guideline-directed pharmacotherapy

#### *Novartis benefits*

- Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis's medicine
- Enhanced reputation, and supporting Novartis' vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation

**Start Date & Duration:** December 2022 for 26 months

**Amendment:** Feb 2024 – to the end of the project

MLRUK2402275858

---

**Source URL:** <https://www.novartis.com/uk-en/about/partnerships/collaborative-working/imperial-college-healthcare-nhs-trust-hammersmith-hospital-lipids-department>

### **List of links present in page**

- <https://www.novartis.com/uk-en/uk-en/about/partnerships/collaborative-working/imperial-college-healthcare-nhs-trust-hammersmith-hospital-lipids-department>